Investors

Corporate Profile
Geron is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Imetelstat is currently being tested in two clinical trials: IMbark™, a Phase 2 trial in myelofibrosis (MF) and IMerge™, a Phase 2/3 trial in myelodysplastic syndromes (MDS). These clinical trials are being conducted by Janssen Biotech, Inc., under a collaboration and license agreement, in which Janssen were granted the exclusive rights to develop and commercialize imetelstat worldwide for all indications in oncology, including hematologic myeloid malignancies, and all other human therapeutic uses.

Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides them with the capacity for limitless, uncontrolled proliferation. Using Geron’s proprietary nucleic acid chemistry, imetelstat was designed as an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation. Early clinical data, including molecular responses in essential thrombocythemia (ET) and remissions, including reversal of bone marrow fibrosis in MF, suggest imetelstat may have disease-modifying activity by inhibiting the progenitor cells of the malignant clones for the underlying diseases.
Recent NewsMore >>
DateTitle 
Aug 9, 2017Geron Corporation Reports Second Quarter 2017 Financial ResultsPrinter Friendly Version
Jul 31, 2017Geron Announces Updates to Imetelstat Clinical DevelopmentPrinter Friendly Version
May 9, 2017Geron Corporation Reports First Quarter 2017 Financial Results and Recent EventsPrinter Friendly Version
Upcoming EventsMore >>
To be announced.
Corporate Presentation
Download Documentation May 2017
Stock Information
GERN (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$2.03
Change (%) Stock is Down 0.03 (1.46%)
Volume818,152
Data as of Aug 18, 2017 4:00 p.m. ET
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Contact Information

Anna Krassowska, Ph.D.
E-mail: investor@geron.com

 Print Page |  E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts